Medicines
Discover all available medicines and treatments
Discover all available medicines and treatments
Brand: Valstar
Valrubicin is an antineoplastic antibiotic used for the treatment of bladder cancer. It is a semisynthetic analog of doxorubicin and exerts its cytotoxic effects by intercalating into DNA, inhibiting topoisomerase II, and generating free radicals. This leads to cell cycle arrest and apoptosis of cancer cells. Valrubicin is specifically indicated for the treatment of carcinoma in situ (CIS) of the urinary bladder.
Treatment of carcinoma in situ (CIS) of the urinary bladder.
Outcome:
Increased valrubicin toxicity
Mechanism:
Inhibition of valrubicin metabolism
Outcome:
Increased risk of bleeding
Mechanism:
Additive effects on coagulation
Outcome:
Potential for reduced valrubicin absorption
Mechanism:
Chelation
Most likely new formulation: Localized sustained-release formulation for intravesical administration (2025, 30% confidence)
Based on current usage trends and clinical trial data, there is a low probability (<5%) of a change in FDA regulatory status within the next 2 years.
Antineoplastic Agent, Anthracycline Antibiotic
Anthracycline